This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
Infection (75.47%, 160/212) and heartfailure (51.42%, 109/212) were common comorbidities. Demographic, clinical, and diagnostic data, as well as follow-up outcomes, were reviewed. In-hospital mortality was 5.19% (11/212), with follow-up mortality of 20.28% (43/212).
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
Objectives To estimate the long-term survival of two cohorts of people diagnosed with heartfailure 10 years apart and to assess differences in patient characteristics, clinical guideline compliance and survival by diagnosis setting. in the 2011/2012 cohort), 10-year survival was 20.8%, and 15-year survival 11.1%.
Introduction Heartfailure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. Treatment is complicated by side effects and comorbidities. Statistical significance is determined at p<0.05.
Objectives We aim to assess the association of cardiovascular medications with outcomes of patients referred to the diagnostic heartfailure (HF) clinic with symptoms or signs of possible HF, raised N-terminal pro-brain-type natriuretic peptide (NT-proBNP) but no evidence of HF on transthoracic echocardiography (TTE).
BackgroundCarotid intimamedia thickness (CIMT) and carotid distensibility are markers of arterial change; however, little is known of the association with incident heartfailure (HF). We aimed to assess this.MethodsThis was a longitudinal analysis of data from the British Regional Heart Study, a prospective cohort study.
The different risk of new-onset, chronic, worsening, and advanced heartfailure. CI, confidence interval; HF, heartfailure; OR, odds ratio. Abstract Aims Heartfailure (HF) is a chronic and progressive syndrome associated with a poor prognosis.
This study aimed to assess whether statin use could lead to better outcomes among individuals with AF.Methods and ResultsWe enrolled 397 787 patients with AF from January 1, 2012 to December 31, 2020. We analyzed 288 958 patients with newly diagnosed AF (mean age, 73 years; 44% women; mean CHA2DS2VASc score, 3.5).
Methods Patients were retrospectively evaluated between January 2012 and June 2020. Clinical contexts leading to diagnosis were SCD in 3 (6%), ventricular arrhythmias in 15 (29%), chest pain in 8 (15%), heartfailure in 6 (12%) and familial screening in 20 (38%).
Methods and results The registry enrolled women from 51 countries from 2012 to 2018. Eligibility included: (i) a peripartum state, (ii) signs or symptoms of heartfailure, (iii) left ventricular (LV) ejection fraction ≤45%, (iv) exclusion of alternative causes of heartfailure. Overall, 66.1%
The aim of this study was to investigate the association of preoperative imaging and haemodynamic data derived from echocardiography (ECHO), cardiac magnetic resonance (CMR) and right heart catheterisation (RHC) with postoperative outcomes following TVS. The primary outcome was a composite of mortality and congestive heartfailure at 1 year.
One of these diseases is heartfailure – a condition in which the heart is unable to pump enough blood to the organs in our body. Unfortunately, the number of patients with heartfailure continues to grow. Of course, there is drug treatment for heartfailure, but it is not always sufficient.
Adverse CVD outcomes was defined as a composite of incident heartfailure, incident atrial fibrillation / flutter, incident myocardial infarction or all-cause mortality. OSA in persons with cancer increased the risk of heartfailure, atrial fibrillation / flutter and myocardial infarction.
Generalized linear mixed‐effects models estimated the association of payment model (including the ability to bill to interpret imaging tests) and the use of cardiac imaging and quantified variation in cardiac imaging.
METHODS:The J-HOP study enrolled outpatients with ≥1 cardiovascular risk factor between 2005 and 2012, with follow-up until March 2015 and extended follow-up from December 2017 to May 2018. 2.00] for overall cardiovascular disease and 2.68 [95% CI, 1.34–5.38]
Patients who received thrombolysis and subsequently underwent endovascular therapy for acute ischemic stroke between 2012 and 2022 were included. Patients were separated into two groups depending on whether or not rescue angioplasty or stenting was performed. Median NIHSS on admission was lower in the tandem occlusion group (15 vs 18, 0.02).
Introduction:Pediatric heart transplant (PHT) recipient survival has improved. Yet, neurologic morbidity related to heartfailure and its treatment persist. Stroke, Volume 56, Issue Suppl_1 , Page ATP261-ATP261, February 1, 2025.
Patients included were of Hispanic origin presenting between 2012 and 2022 who underwent thrombectomy for acute ischemic stroke. We performed this retrospective cohort analysis to assess the impact of poorly controlled diabetes, defined as HbA1C of 9.0% or greater.
e5 Article Download PDF Google Scholar 3 RNW Hauer, MGPJ Cox, JA Groeneweg Impact of new electrocardiographic criteria in arrhythmogenic cardiomyopathy Front Physiol, 3 (2012), p. J Electrocardiol, 42 (2009), pp.
One situation is decompensated advanced systolic heartfailure with large left ventricle. 2012; 126: 138-141. Indian Heart J. Measurement of E’ is useful in differentiation of pseudo normalization in the mitral inflow from the normal pattern. References Beaudoin J et al. Circulation. Kumar V et al. L wave in echo Doppler.
IF the Patient is Younger and Athletic: The mechanism of AFib in younger, athletic individuals is often heavily influenced by increased vagal tone ( Rao and Shipon — ACC, 2019 — and — Calvo et al — Br J Sports Med, 2012 ). Ballatore et al — Medicina (Kaunas) 55(8): 497, 2019 — and — Page et al — Circulation 107:1141-1145, 2003 ).
This study describes secular trends in CVD events by individual condition from 2012 to 2022. Results Overall, the event rate ratios (RRs) for IHD, MI, AF and AAA all fell between 2012 and 2021 after adjustment for age, sex and deprivation. and PAD (RR 1.8).
We aimed to develop standardized, nationally representative CVD events and selected possible CVD treatment–related complication hospitalization costs for use in cost-effectiveness analyses.METHODS:Nationally representative costs were derived using publicly available inpatient hospital discharge data from the 2012-2018 National Inpatient Sample.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
plus drug supply BEST-D pilot trial of vitamin D (2012-2014) Tishcon: free drug supply only Big Data Institute (2018-2021) Novartis Pharma AG Switzerland: £272K Can wearables improve the prediction of all-cause mortality, cardiovascular disease, and cancer in UK Biobank? plus drug supply Bayer: £1.8M
In addition to profound acute heartfailure, the patient suffered from electrical storm. Was her outcome to be expected for ostial RCA OMI? Or was it out of proportion, perhaps worsened by the sympathetic surge? We will never know for certain. Multidisciplinary critical care management of electrical storm. link] Mostofsky, E.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content